» Articles » PMID: 33156626

Electron-Accepting Micelles Deplete Reduced Nicotinamide Adenine Dinucleotide Phosphate and Impair Two Antioxidant Cascades for Ferroptosis-Induced Tumor Eradication

Overview
Journal ACS Nano
Specialty Biotechnology
Date 2020 Nov 6
PMID 33156626
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Ferroptotic antitumor therapy has been compromised by various intracellular antioxidants, particularly glutathione and thioredoxin. Both are cofactors of glutathione peroxide 4 (GPX4) that act against oxidative stress catalyzing the reduction of lipid peroxides. It was postulated that tailored polymer micelles could enhance ferroptotic antitumor efficacy diminishing glutathione and thioredoxin under hypoxia. The aim was to engineer hypoxia-responsive micelles for selective enhancement of ferroptotic cell death in solid tumor. The polymer contains hydrophilic poly(ethylene glycol) (PEG) that is linked by azobenzene linker with nitroimidazole-conjugated polypeptide. The tailored polymer could self-assemble into nanoscale micelles to encapsulate RAS-selective lethal small molecule 3, a covalent GPX4 inhibitor. Under hypoxia, the azobenzene moiety enabled PEG shedding and enhanced micelles uptake in 4T1 cells. Likewise, the nitroimidazole moiety was reduced by the overexpressed nitroreductase with reduced nicotinamide adenine dinucleotide phosphate (NADPH) as the cofactor, resulting in transient depletion of NADPH. This impaired both the glutathione and thioredoxin redox cycle, leading to diminished intracellular glutathione and thioredoxin. The selective potency of ferroptotic micelles in depleting NADPH, glutathione and thioredoxin was further verified in the 4T1 tumor xenograft mice model. This work highlights the role of hypoxia-responsive polymers in enhancing the potency of ferroptotic inducers against solid tumors without additional side effects to healthy organs.

Citing Articles

Hypoxia-responsive nanoparticles for fluorescence diagnosis and therapy of cancer.

Zhang Y, Xing J, Jiang J, Liao M, Pan G, Wang Y Theranostics. 2025; 15(4):1353-1375.

PMID: 39816693 PMC: 11729551. DOI: 10.7150/thno.104190.


Integrating oxygen-boosted sonodynamic therapy and ferroptosis engineered exosomes for effective cancer treatment.

Wu M, Zhang Z, Li D, Ruan X, Yang J, Chen S Theranostics. 2025; 15(1):68-85.

PMID: 39744220 PMC: 11667237. DOI: 10.7150/thno.102977.


Asymmetrically PEGylated and amphipathic heptamethine indocyanine dyes potentiate radiotherapy of renal cell carcinoma via mitochondrial targeting.

Wu Z, Huang X, Wu C, Zhou Y, Gao M, Luo S J Nanobiotechnology. 2024; 22(1):756.

PMID: 39695771 PMC: 11658457. DOI: 10.1186/s12951-024-03012-3.


GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via β-Klotho-Mediated Ferroptosis Inhibition.

Tian S, Zhou S, Wu W, Lin Y, Wang T, Sun H Adv Sci (Weinh). 2024; 12(4):e2409781.

PMID: 39630101 PMC: 11775532. DOI: 10.1002/advs.202409781.


Exploring the Updated Roles of Ferroptosis in Liver Diseases: Mechanisms, Regulators, and Therapeutic Implications.

Ge T, Wang Y, Han Y, Bao X, Lu C Cell Biochem Biophys. 2024; .

PMID: 39543068 DOI: 10.1007/s12013-024-01611-3.